community.elabeln.com/experiments.php?mode=edit&id=314
#314 Cell Biology Complete

MTS viability: HeLa + doxorubicin (9-pt dose)

Started on
Tags
cell-viability MTS-assay doxorubicin HeLa cytotoxicity
Custom ID

This template captures an MTS-based cytotoxicity assay of doxorubicin against HeLa cervical carcinoma cells in a 96-well format, generating a 9-point dose-response curve and EC50 estimate.

Goal: measure the cytotoxic effect of doxorubicin (anthracycline DNA-intercalator) on proliferating HeLa cells over a log-scale 9-point dose range (10 µM → 1.5 nM, 3-fold serial dilution), with 4 replicate wells per dose, and extract EC50, Hill slope, and assay window (Z’) for QC.

Method overview: 5,000 HeLa cells seeded per well in 100 µL DMEM + 10% FBS in a Corning 96-well flat-bottom plate, 24 hours pre-treatment. Doxorubicin diluted from 10 mM DMSO stock in growth media to 2× working concentrations, with vehicle control matched at 0.1% DMSO. 100 µL of 2× drug added to wells for 1× final concentration. 24 hours treatment at 37°C / 5% CO₂. 20 µL CellTiter 96 AQueous One Solution (MTS + PES) added per well, incubated 4 hours, absorbance read at 490 nm on plate reader. Blank-subtracted viability calculated relative to vehicle control wells. 4PL fit performed in GraphPad Prism.

Expected: Sigmoidal dose-response with EC50 in the 0.3-0.6 µM range for HeLa (published range), Hill slope 1.0-1.8, R² > 0.99, Z’ > 0.5. Background < 0.1 A490; vehicle-control viability normalized to 100%; high-dose viability < 10%.

Last saved: 34 seconds ago
12 fields loaded from MTS Cell Viability baseline (SOP v1.4)
Cells
Cell line
select
HeLa, MCF7, A549, HCT116, primary culture
Seed density
number
5000cells/well
Pre-treatment time
number
24h
Compound
Compound
text
Doxorubicin
High dose
number
10µM
Dilution factor
number
3
Dose points
number
9
Replicates
number
4
Treatment time
number
24h
Readout & QC
Readout
select
MTS, AlamarBlue, CellTiter-Glo, trypan blue
EC50
number
0.41µM
Z′-factor
number
0.82
plate_layout.pdf
224 KB
reader_A490_raw.csv
18 KB
dose_response_4PL.xlsx
92 KB
01
Trypsinize HeLa stock + count: 4.8 × 10⁵ cells/mL in DMEM+10%FBS
95% viability by trypan blue
0:10
02
Seed 100 µL/well = 5,000 cells/well in inner 60 wells, outer rows H₂O
0:15
03
Incubate plate 24 h at 37°C / 5% CO₂
24:00
04
Prepare doxorubicin 9-point 3-fold dilution series in media (2× final)
High 20 µM → low 3 nM (2×)
0:15
05
Add 100 µL of 2× drug to wells, vehicle-only to control wells (0.1% DMSO)
0:10
06
Incubate plate 24 h at 37°C / 5% CO₂
Treatment 24 h
24:00
07
Add 20 µL CellTiter 96 AQueous One per well, swirl gently
0:03
08
Incubate 4 h at 37°C / 5% CO₂
Color develops to orange-brown
4:00
09
Read A490 on plate reader; export CSV
BioTek Synergy H1 · run 06:04:14:32
0:03
10
Calculate blank-subtracted viability + 4PL fit in Prism, extract EC50 + Z'
EC50 0.41 µM · Z' 0.82 · R² 0.998
0:25
A B C D E F G
1 Dose (µM) Rep 1 Rep 2 Rep 3 Rep 4 Mean A₄₉₀ % Viability
2 10 0.121 0.118 0.115 0.122 0.119 5
3 3.3 0.140 0.135 0.142 0.138 0.139 8
4 1.1 0.226 0.218 0.232 0.221 0.224 22
5 0.37 0.508 0.512 0.495 0.519 0.509 50
6 0.12 0.788 0.795 0.781 0.792 0.789 80
7 0.041 0.872 0.879 0.865 0.880 0.874 88
8 0.014 0.925 0.918 0.931 0.924 0.924 93
9 0.0045 0.948 0.939 0.951 0.945 0.946 95
10 0.0015 0.962 0.955 0.968 0.959 0.961 97
11 vehicle 0.992 1.005 0.985 1.000 0.996 100
12 blank 0.072 0.068 0.074 0.070 0.071 —
CellTiter 96 AQueous One Solution (MTS + PES)
G3580 · Lot 0000465812
In stock
Doxorubicin HCl (10 mM in DMSO)
D1515 · Lot SLBR9421A
In stock
DMSO (cell culture grade, vehicle ctrl)
D2650 · Lot SLBT8847A
In stock
DMEM + GlutaMAX (high glucose)
10566016 · Lot 2722164
In stock
FBS, heat-inactivated (HI-FBS)
16140071 · Lot 2722084
Low
Doxorubicin stock + 10× working aliquots
-20 °C · Freezer C-2 · Drawer 1 · Box CPD-DOX-2026
×8
CellTiter 96 reagent (5 mL working)
-20 °C protected from light · Freezer C-2
×2
Plate reader raw data + Prism workbook
Cloud · /viability/2026-06/DOX-001/
×3
Visibility
Chen LabJ. Chen
Can write
J. ChenDr. M. Liu




Use Ctrl + click to add text